Global Cancer Vaccine Market & Clinical Trials Outlook 2028

July 2022 | 600 pages | ID: G1CC18B328DEEN
Kuick Research

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Cancer Vaccine Market & Clinical Trials Outlook 2028 Highlights:

• Global and Regional Market Size Insight 2022 Till 2028
• Cancer Vaccine Market Insight & Forecast By 10 Countries 2022 Till 2028
• Cancer Vaccine Market Insight & Forecast By 10 Different Cancers 2022 Till 2028
• Approved Cancer Vaccines Patent, Price, & Dosage Analysis
• Insight On More Than 350 Cancer Vaccines in Clinical Trials
• Cancer Vaccines Trials Insight By Company, Country and Indication
• Insight On More Than 20 Cancer Vaccines Commercially Available In Market

The use of vaccines for the prevention of infectious disease represents one of the greatest achievements in modern medicine. Owing to their advantages, research studies have also focused to explore the potential of vaccines in the prevention or management of chronic diseases including cancer. Cancer vaccine represents unique approach to cancer therapy which alters the interaction of the host and the tumor, enlisting the patient’s tumor response to attack cancer cells. Further, the immunologic memory associated with the administration of vaccines also gained the interest of researchers to invest in this segment.

Till date, both therapeutic as well as preventive cancer vaccines have gained entry into the global market. Several cancer vaccines including Gardasil, Gardasil 9, Cecolin, or Cervarix have been approved to prevent HPV infection which target high risk HPV strains responsible for nearly all cervical cancers and are also linked to some throat, anal, and other cancers. In contrast, Provenge was the first therapeutic vaccine globally approved in 2010 for the management of prostate cancer. Apart from this, CemaVax, Riavax, and Vaxira have also been approved for the management of non-small cell lung cancer and pancreatic cancer. The entrance of vaccines has shown to greatly transform the paradigm of cancer treatment.

Currently, the pipeline of cancer vaccine is highly crowded which are increasingly reporting encouraging success in clinical trials across wide range of cancers. Several vaccines are also awaiting marketing approval or commercialization. For instance, US FDA is currently reviewing BLA application for N-803 plus Bacillus Calmette-Gu?rin as treatment for patients with BCG-unresponsive non-muscle invasive bladder cancer. Apart from this, Cervac has been approved in India and is expected to be available in the market soon. The presence of wide range of clinical pipeline products indicates strong future presence of the market.

With the continuous research and development activities in this domain, scientists have also developed other enhanced platforms for vaccine development including mRNA vaccines, personalized neoantigen cancer vaccines, stem cells, and others. Although these are present in early stages of clinical development, these represent huge potential across wide range of cancers. Further, the market will also experience growth with the introduction of artificial intelligence algorithms which aid in the precise detection of neoantigens and also factor the early development of companies. Several top players in the market has utilized machine learning to develop their proprietary artificial intelligence algorithm for the characterization of neoantigens and ultimately developing personalized neoantigen cancer vaccines.

In last few years, pharmaceutical companies have also entered into collaboration with artificial intelligence players to develop potential cancer vaccines. For instance in 2022, CureVac entered into research and option agreement with myNEO which will aim to identify specific antigens found on the surface of tumors for the development of vaccines. To achieve this goal, myNEO will leverage its biological datasets and its integrated machine learning and bioinformatics platform to identify and validate specific antigen targets predicted to elicit strong immune response. Apart from this, myNEO also collaborated with Abera Bioscience to develop personalized cancer vaccines. Other key players in the global market are Argos Therapeutics, Nykode Therapeutics, Merck, Regeneron, GlaxoSmithKline, CureVac, Dendreon, Sanofi, and OSE Immunotherapeutics.

As per our report findings, the global cancer vaccine market is expected to surpass US$ 15 Billion by 2028. The significant increase in the growth of market is mainly attributed to encouraging sales of HPV cancer vaccines and rising awareness among individuals regarding the benefits of HPV vaccination. Apart from this, several investigational cancer vaccines have progressed towards late stage clinical trials and are expected to gain market authorization, which will also have a positive impact on the growth of market.

Contents

1. INTRODUCTION TO CANCER VACCINES

2. MECHANISM OF CANCER VACCINES

2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. GLOBAL CANCER VACCINE MARKET OVERVIEW

3.1 Current Market Scenario
3.2 Future Market Opportunity

4. CANCER VACCINE MARKET INSIGHT BY REGION

4.1 US
4.2 Europe
4.3 China
4.4 Japan
4.5 India
4.6 South Korea
4.7 Australia
4.8 Cuba
4.9 Canada
4.10 UK

5. CANCER VACCINE MARKET INSIGHT BY INDICATION

5.1 Human papillomavirus Associated Cancer
5.2 Lung Cancer
5.3 Pancreatic Cancer
5.4 Prostate Cancer
5.5 Bladder Cancer
5.6 Melanoma
5.7 Breast Cancer
5.8 Colorectal Cancer
5.9 Glioblastoma
5.10 Ovarian Cancer

6. APPROVED CANCER VACCINES – PRICE, & DOSAGE ANALYSIS

This Chapter Give Insight On 11 Cancer Vaccine Commercially Available In Market

7. GLOBAL CANCER VACCINES CLINICAL PIPELINE OVERVIEW

7.1 By Company
7.2 By Country
7.3 By Patient Segment/Disease Stage
7.4 By Phase

8. GLOBAL CANCER VACCINES CLINICAL TRIALS INSIGHT BY COMPANY, INDICATION & PHASE

8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-I
8.5 Phase-I/II
8.6 Phase-II
8.7 Phase-III/II
8.8 Phase-III
8.9 Preregistration
8.10 Registered

9. MARKETED CANCER VACCINES CLINICAL INSIGHT BY COMPANY & INDICATION

10. COMPETITIVE LANDSCAPE

10.1 Anixa Bioscience
10.2 Argos Therapeutics
10.3 AstraZeneca
10.4 BioNTech
10.5 Bristol Myers Squibb
10.6 Champions Oncology
10.7 CureVac
10.8 Elicio Therapeutics
10.9 ETheRNA
10.10 GlaxoSmithKline
10.11 ImmunityBio
10.12 Imugene
10.13 In3Bio
10.14 Merck
10.15 Mayo Clinic
10.16 Nykode Therapeutics
10.17 Regeneron
10.18 Roche
10.19 TVAX Biomedical
10.20 UbiVac
10.21 Ultimovacs
10.22 VBI vaccines

List Of Figures

LIST OF FIGURES

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines
Figure 3-1: Global – Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 3-2: Cancer Vaccine - Market Size by Region (US$ Million), 2021
Figure 3-3: Cancer Vaccine - Market Size by Region (%), 2021
Figure 3-4: Global – Cancer Vaccine Market Size (US$ Billion), 2022 - 2028
Figure 4-1: US – Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 4-2: US vs. ROW – Cancer Vaccine Market Size (US$ Million), 2021
Figure 4-3: US vs. ROW – Cancer Vaccine Market Size (%), 2021
Figure 4-4: US – Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 4-5: Europe – Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 4-6: Europe vs. ROW – Cancer Vaccine Market Size (US$ Million), 2021
Figure 4-7: Europe vs. ROW – Cancer Vaccine Market Size (%), 2021
Figure 4-8: Europe – Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 4-9: China – Market Share of HPV Vaccine Suppliers (%), 2020
Figure 4-10: China – Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 4-11: China – Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 4-12: Japan – Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 4-13: Japan – Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 4-14: India – Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 4-15: India – Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 4-16: South Korea – Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 4-17: South Korea – Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 4-18: Australia – Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 4-19: Australia – Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 4-20: Cuba – Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 4-21: Cuba – Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 4-22: Canada – Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 4-23: Canada – Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 4-24: UK – Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 4-25: UK – Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 5-1: Global – HPV Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 5-2: Global – HPV Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 5-3: Global – Lung Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 5-4: Global – Lung Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 5-5: Global – Pancreatic Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 5-6: Global – Pancreatic Cancer Vaccine Market Size (US$ Million), 2022 – 2028
Figure 5-7: Global – Prostate Cancer Vaccine Market Size (US$ Million), 2020 & 2021
Figure 5-8: Global – Prostate Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 5-9: Global – Bladder Cancer Vaccine Market Size (US$ Million), 2022 - 2028
Figure 5-10: Global – Melanoma Vaccine Market Size (US$ Million), 2025 - 2028
Figure 5-11: Global – Breast Cancer Vaccine Market Size (US$ Million), 2024 - 2028
Figure 5-12: Global – Colorectal Cancer Vaccine Market Size (US$ Million), 2025 – 2028
Figure 5-13: Global – Glioblastoma Vaccine Market Size (US$ Million), 2025 - 2028
Figure 5-14: Global – Ovarian Cancer Vaccine Market Size (US$ Million), 2025 - 2028
Figure 6-1: Gardasil – Approval Year by Region
Figure 6-2: Gardasil 9 – Approval Year by Region
Figure 6-3: US – Gardasil Approval Year by Indication
Figure 6-4: Canada – Gardasil Approval Year by Indication
Figure 6-5: Gardasil 9 – Patent Expiration Year by Region
Figure 6-6: US – Cost of 5ml & Per Unit Cost of Gardasil 9 Intramuscular Suspension (US$), July’2022
Figure 6-7: UK – Per Unit Cost of Gardasil & Gardasil 9 Injection (GBP/US$), July’2022
Figure 6-8: South Korea – Per Unit Cost of Gardasil Injection (KRW/US$), July’2022
Figure 6-9: Global – Gardasil/ Gardasil 9 Sales Value (US$ Million), Q1’2021 & Q1’2022
Figure 6-10: Global – Gardasil/ Gardasil 9 Sales Value (US$ Million), 2018 - 2021
Figure 6-11: Global – Gardasil/ Gardasil 9 Quarterly Sales Value (US$ Million), 2021
Figure 6-12: Global – Gardasil/ Gardasil 9 Quarterly Sales Value (US$ Million), 2020
Figure 6-13: Cervarix – Approval Year by Region
Figure 6-14: UK – Per Unit Cost of Cervarix Injection (GBP/US$), July’2022
Figure 6-15: UK – Cost of Single Cycle & Total Cost of Treatment with Cervarix (GBP/US$), July’2022
Figure 6-16: South Korea – Per Unit Cost of Cervarix Injection (KRW/US$), July’2022
Figure 6-17: Cervarix – Sales Value by Region (Euro/US$ Million), Q1’2022
Figure 6-18: Cervarix – Sales Value by Region (%), Q1’2022
Figure 6-19: Global – Cervarix Sales Value (Euro/US$ Million), 2019 - 2021
Figure 6-20: Europe – Cervarix Sales Value (Euro/US$ Million), 2019 - 2021
Figure 6-21: Cervarix – Sales Value by Region (Euro/US$ Million), 2021
Figure 6-22: Cervarix – Sales Value by Region (%), 2021
Figure 6-23: US – Cost of 250ml & Per Unit Cost of Proenge Intraveneous Suspension (US$), July’2022
Figure 6-24: India – Per Unit Cost of Mycidac-C Injection (INR/US$), July’2022
Figure 7-1: Global - Number of Cancer Vaccines in Clinical Trials by Company, 2022 till 2028
Figure 7-2: Global - Number of Cancer Vaccines in Clinical Trials by Country, 2022 till 2028
Figure 7-3: Global - Number of Cancer Vaccines Clinical Trials by Disease Stage, 2022 till 2028
Figure 7-4: Global - Number of Cancer Vaccine in Clinical Trials by Phase, 2022 till 2028